BRPI0518928A2 - suspensço oftÁlmica aquosa de rebamipide cristalino - Google Patents

suspensço oftÁlmica aquosa de rebamipide cristalino

Info

Publication number
BRPI0518928A2
BRPI0518928A2 BRPI0518928-4A BRPI0518928A BRPI0518928A2 BR PI0518928 A2 BRPI0518928 A2 BR PI0518928A2 BR PI0518928 A BRPI0518928 A BR PI0518928A BR PI0518928 A2 BRPI0518928 A2 BR PI0518928A2
Authority
BR
Brazil
Prior art keywords
rebamipide
aqueous
crystalline
suspension
aqueous ophthalmic
Prior art date
Application number
BRPI0518928-4A
Other languages
English (en)
Inventor
Takakuni Matsuda
Shogo Hiraoka
Yuso Tomohira
Shinichi Ishikawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0518928A2 publication Critical patent/BRPI0518928A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SUSPENSçO OFTÁLMICA AQUOSA DE REBAMIPIDE CRISTALINO. A invenção provê um produto oftálmico contendo rebamipide, que tem uma transparência suficiente para ser de sensação agradável e tem um pH neutro a fracamente ácido para não danificar a ceratoconjuntiva de um paciente sofrendo de olho seco. Uma suspensão aquosa de rebamipide cristalino tem uma transparência aperfeiçoada é provida através de adição de uma solução aquosa de rebamipide dissolvido por uma base tal como hidróxido de sódio ou uma solução aquosa de um sal de rebamipide a uma solução ácida aquosa tal como ácido clorídrico contendo pelo menos um dos compostos selecionados de polímeros e tensoativos solúveis em água, e misturando os mesmos.
BRPI0518928-4A 2004-11-15 2005-11-11 suspensço oftÁlmica aquosa de rebamipide cristalino BRPI0518928A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004330140 2004-11-15
PCT/JP2005/021178 WO2006052018A1 (en) 2004-11-15 2005-11-11 Aqueous ophthalmic suspension of crystalline rebamipide

Publications (1)

Publication Number Publication Date
BRPI0518928A2 true BRPI0518928A2 (pt) 2008-12-16

Family

ID=36336674

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518928-4A BRPI0518928A2 (pt) 2004-11-15 2005-11-11 suspensço oftÁlmica aquosa de rebamipide cristalino

Country Status (16)

Country Link
US (2) US9211254B2 (pt)
EP (1) EP1812000A4 (pt)
JP (3) JP4934587B2 (pt)
KR (1) KR101271959B1 (pt)
CN (1) CN100594901C (pt)
AR (2) AR052779A1 (pt)
AU (1) AU2005302908B2 (pt)
BR (1) BRPI0518928A2 (pt)
CA (1) CA2584017C (pt)
HK (1) HK1112718A1 (pt)
MX (1) MX2007005782A (pt)
MY (1) MY152867A (pt)
RU (1) RU2398585C2 (pt)
SG (1) SG156692A1 (pt)
TW (1) TWI363626B (pt)
WO (1) WO2006052018A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808375A (en) * 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
EP2285413B1 (en) * 2008-06-19 2012-08-08 Otsuka Pharmaceutical Co., Ltd. A pharmaceutical composition
US20100247666A1 (en) * 2009-03-24 2010-09-30 Macleod Steven K Method for Preparing Suspensions of Low-Solubility Materials
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
UA114600C2 (uk) * 2011-03-24 2017-07-10 Оцука Фармасьютікал Ко., Лтд. Фармацевтична композиція для лікування захворювання у порожнині рота, що містить ребаміпід
TW201322982A (zh) * 2011-11-01 2013-06-16 Otsuka Pharma Co Ltd 用於治療前眼疾病之藥劑，該藥劑包含瑞巴派特及眼淚保持劑
SA113340675B1 (ar) * 2012-06-26 2015-08-16 استيش. كو.، ليمتد أدوية ريباميبايد تحضيرية جديدة، طريقة تحضيرها واستخدامها
KR101692578B1 (ko) 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
US20160114048A1 (en) * 2013-05-16 2016-04-28 Universiteit Antwerpen Thermolabile drug release formulation
TWI697337B (zh) * 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
CN104586762A (zh) * 2014-04-11 2015-05-06 广州仁恒医药科技有限公司 含有瑞巴派特的药物组合物及其制备方法
JP6854587B2 (ja) * 2015-04-17 2021-04-07 ロート製薬株式会社 医薬製剤
KR101718733B1 (ko) * 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제
KR102307958B1 (ko) 2015-10-01 2021-10-05 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
KR20170039347A (ko) 2015-10-01 2017-04-11 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
JP6732441B2 (ja) * 2015-12-11 2020-07-29 ロート製薬株式会社 局所粘膜適用水性組成物
KR101840256B1 (ko) * 2017-09-21 2018-03-21 대우제약 주식회사 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법
KR101923519B1 (ko) 2018-06-26 2019-02-27 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR20200019451A (ko) 2018-08-14 2020-02-24 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR102615076B1 (ko) * 2021-07-14 2023-12-19 대우제약 주식회사 안정한 레바미피드 점안제의 대용량 제조 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50121414A (pt) 1974-02-18 1975-09-23
JPS55139319A (en) 1979-04-13 1980-10-31 Furointo Sangyo Kk Activation of drug soluble in alkali and acid
US5366985A (en) 1991-03-27 1994-11-22 Senju Pharmaceutical Co., Ltd. Method for preparation of an aqueous suspension
JP2808378B2 (ja) * 1991-03-27 1998-10-08 武田薬品工業株式会社 水性懸濁液剤の製造法
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
JP3093661B2 (ja) * 1995-10-12 2000-10-03 大塚製薬株式会社 眼疾患治療剤
JPH09301855A (ja) * 1996-05-13 1997-11-25 Fuairudo Kk 健康用部材
KR20010012188A (ko) 1997-05-14 2001-02-15 요시다 쇼지 재분산성이 양호한 수성 현탁액제
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
GB9810859D0 (en) * 1998-05-20 1998-07-22 Zeneca Ltd Crystallisation process
AU2002313236B2 (en) * 2001-06-14 2007-07-26 Otsuka Pharmaceutical Co., Ltd. Medicinal compositions

Also Published As

Publication number Publication date
AU2005302908A1 (en) 2006-05-18
SG156692A1 (en) 2009-11-26
AR052779A1 (es) 2007-04-04
RU2007122392A (ru) 2008-12-20
MY152867A (en) 2014-11-28
CN100594901C (zh) 2010-03-24
HK1112718A1 (en) 2008-09-12
US9533052B2 (en) 2017-01-03
EP1812000A4 (en) 2012-08-08
TW200621252A (en) 2006-07-01
US20160101183A1 (en) 2016-04-14
CN101056636A (zh) 2007-10-17
RU2398585C2 (ru) 2010-09-10
US20070287729A1 (en) 2007-12-13
CA2584017C (en) 2013-08-27
KR20070092965A (ko) 2007-09-14
KR101271959B1 (ko) 2013-06-10
US9211254B2 (en) 2015-12-15
TWI363626B (en) 2012-05-11
JP2008519759A (ja) 2008-06-12
AU2005302908B2 (en) 2011-03-31
JP2012092139A (ja) 2012-05-17
MX2007005782A (es) 2007-07-19
AR108955A2 (es) 2018-10-10
WO2006052018A1 (en) 2006-05-18
JP2014077012A (ja) 2014-05-01
CA2584017A1 (en) 2006-05-18
JP4934587B2 (ja) 2012-05-16
EP1812000A1 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
BRPI0518928A2 (pt) suspensço oftÁlmica aquosa de rebamipide cristalino
EA201270339A1 (ru) Замещенные производные ксантина
BR112015022483A2 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
BR0214177A (pt) Derivado de benzofenona, agente preventivo ou terapêutico para uma doença em que está envolvida expressão excessiva de ap-1, e, inibidor de ap-1
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
MA31903B1 (fr) Derives de thiazole utilises comme inhibiteur de la pi 3 kinase
EA201001391A1 (ru) Замещенные производные ксантинов и их применение
BRPI0818006B8 (pt) compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas
BRPI0607400A2 (pt) derivados do ácido [isoquinolin-3-(carbonil)amino]-propiÈnico como inibidores dos fatores xi e ix para o tratamento de trombose
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
BRPI0708685B8 (pt) composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BR112012024773A2 (pt) compósito de celulose, alimento e bebida contendo o mesmo, e processo para produzir um compósito de celulose
Lee et al. Homocysteine enhances MMP-9 production in murine macrophages via ERK and Akt signaling pathways
MY150250A (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
MA38488A1 (fr) Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate
UA87506C2 (ru) Применение электролита как стабилизатора ингибитора
BRPI0908432A2 (pt) composições antimicrobianas tópicas
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
NO20063865L (no) Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter
MA33760B1 (fr) Dérivés spirolactames et leurs utilisations

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2487 DE 04-09-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.